Posted by Michael Wonder on 30 Mar 2022
Roche, Government miss deadline for Tecentriq reimbursement talks
30 March 2022 - Roche Korea and the Government failed to reach an agreement over the reimbursement rate of Tecentriq (atezolizumab) for the treatment of hepatocellular carcinoma within the negotiation deadline.
Roche Korea said it was actively talking with the Government to win health insurance benefits, but Korean liver cancer patients will have to wait for another month.
